Home
BIVI
BIVI News

Latest BioVie Inc. (BIVI) News on September 15, 2025

BioVie Inc. Announces Closing of $12 Million Public Offering

GlobeNewswire

a month ago

BioVie Inc. Announces Closing of $12 Million Public Offering

ACCESS Newswire

a month ago

New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

GlobeNewswire

3 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

GlobeNewswire

3 months ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

ACCESS Newswire

3 months ago

New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST

ACCESS Newswire

3 months ago

New to The Street Announces Upcoming Bloomberg Air Dates Featuring FLOKI, BioVie Pharmaceuticals, Beeline, Arrive AI, and Commercialville

ACCESS Newswire

4 months ago

BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

GlobeNewswire

4 months ago

BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

GlobeNewswire

4 months ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)

GlobeNewswire

4 months ago

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)

BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

GlobeNewswire

4 months ago

BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth

ACCESS Newswire

5 months ago

New to The Street Airs on Bloomberg TV Saturday, April 26 at 6:30 PM ET Featuring BioVie (NASDAQ: BIVI), Skip Barber Racing School with CFO Michael Berg, CommercialVille.tv, Sustainable Green Team (OTCPK: SGTM) WaterLess Garden, and The Business of Blockchain with Michael Casey

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

GlobeNewswire

5 months ago

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

ACCESS Newswire

5 months ago

New to The Street's FOX Business "Late Night T.V." Special Airs Tonight – Show #650 – Featuring Health In Tech CEO Julia Qian (NASDAQ:HIT), BioVie's Dr. Joseph Palumbo (NASDAQ:BIVI), eXoZymes Co-Founder & VP of Research Tyler Korman (EXOZ), and ARRIVE AI Founder & CEO Dan O'Toole (ARAI)

ACCESS Newswire

5 months ago

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CFO Julia Qian, BIOVie’s Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman — as Sponsored Programming

ACCESS Newswire

5 months ago

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BIOVie’s Dr. Joe Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman — as Sponsored Programming

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming

ACCESS Newswire

5 months ago

New to The Street Announces Bloomberg Television Lineup for Saturday, April 12 at 6:30 PM ET Featuring Health In Tech CEO Julia Qian, BioVie's Dr. Joseph Palumbo, The Sustainable Green Team with Kevin Harrington and Tony Raynor, and eXoZymes Vice President Tyler Korman - as Sponsored Programming

ACCESS Newswire

6 months ago

New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc.

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

GlobeNewswire

6 months ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

ACCESS Newswire

6 months ago

New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and Banzai CEO Joe Davy

ACCESS Newswire

6 months ago

New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI)

New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce

ACCESS Newswire

6 months ago

New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce

ACCESS Newswire

7 months ago

New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tank’s Kevin Harrington and Sustainable Green Team (SGTM)

Is BioVie (NASDAQ:BIVI) In A Good Position To Invest In Growth?

Simply Wall St.

7 months ago

Is BioVie (NASDAQ:BIVI) In A Good Position To Invest In Growth?

ACCESS Newswire

8 months ago

BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

GlobeNewswire

10 months ago

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded

GlobeNewswire

10 months ago

BioVie’s Upcoming Parkinson’s Disease Clinical Trial is Fully Funded

BioVie Inc. Announces Closing of Registered Direct Offering

GlobeNewswire

a year ago

BioVie Inc. Announces Closing of Registered Direct Offering

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

a year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

a year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

a year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

MT Newswires

a year ago

Top Premarket Gainers

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

a year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Announces Stock Offering and Private Placement

TipRanks

a year ago

BioVie Announces Stock Offering and Private Placement

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

GlobeNewswire

a year ago

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

GlobeNewswire

a year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

MT Newswires

a year ago

BioVie Shares Surge After Pricing $6.6 Million Direct Offering, Private Placement of Warrants

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire

a year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

GlobeNewswire

a year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

a year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

GlobeNewswire

a year ago

BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. Announces Closing of Public Offering

GlobeNewswire

a year ago

BioVie Inc. Announces Closing of Public Offering

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

Sector Update: Health Care Stocks Steady Pre-Bell Tuesday

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

BioVie Prices Offering of 1.96 Million Shares, Warrants; Stock Drops Premarket

BioVie Inc. Announces Pricing of Public Offering

GlobeNewswire

a year ago

BioVie Inc. Announces Pricing of Public Offering

MT Newswires

a year ago

BioVie Plans Public Offering; Stock Drops After-Hours

BioVie Inc. Announces Proposed Public Offering

GlobeNewswire

a year ago

BioVie Inc. Announces Proposed Public Offering

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

GlobeNewswire

a year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

MT Newswires

a year ago

BioVie Secures FDA Authorization for Phase 2 Study on Long COVID Treatment

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

GlobeNewswire

a year ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

GlobeNewswire

a year ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

GlobeNewswire

a year ago

BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

GlobeNewswire

a year ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’s Disease

BioVie Inc. Announces Reverse Stock Split

GlobeNewswire

a year ago

BioVie Inc. Announces Reverse Stock Split

Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline

Simply Wall St.

a year ago

Individual investors invested in BioVie Inc. (NASDAQ:BIVI) copped the brunt of last week's US$55m market cap decline

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

a year ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

GlobeNewswire

a year ago

BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

a year ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

GlobeNewswire

a year ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

GlobeNewswire

a year ago

Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

GlobeNewswire

a year ago

BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

GlobeNewswire

a year ago

BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

MT Newswires

a year ago

BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

GlobeNewswire

a year ago

BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

GlobeNewswire

a year ago

BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

GlobeNewswire

a year ago

BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ACCESSWIRE

a year ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

Zacks

2 years ago

Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

GlobeNewswire

2 years ago

BioVie Announces Pipeline Update and Near-Term Clinical Priorities

BioVie Inc. Announces Closing of Public Offering

GlobeNewswire

2 years ago

BioVie Inc. Announces Closing of Public Offering

BioVie Inc. Announces Pricing of Public Offering

GlobeNewswire

2 years ago

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Proposed Public Offering of Common Stock

GlobeNewswire

2 years ago

BioVie Inc. Announces Proposed Public Offering of Common Stock

BioVie Inc. Announces Proposed Public Offering of Common Stoc

GlobeNewswire

2 years ago

BioVie Inc. Announces Proposed Public Offering of Common Stoc

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

GlobeNewswire

2 years ago

BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

GlobeNewswire

2 years ago

BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

Business Wire

2 years ago

Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study

18 Best 52-Week Low Stocks To Buy Now

Insider Monkey

2 years ago

18 Best 52-Week Low Stocks To Buy Now

SurgePays Announces Strategic Partnership with SIN PIN

GlobeNewswire

2 years ago

SurgePays Announces Strategic Partnership with SIN PIN

Provident Financial Holdings To Host Earnings Release Conference Call

GlobeNewswire

2 years ago

Provident Financial Holdings To Host Earnings Release Conference Call

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

GlobeNewswire

2 years ago

PodcastOne (Nasdaq: PODC) Renews Agreement With Award Winning Our Fake History Podcast

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

GlobeNewswire

2 years ago

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

2 years ago

bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Business Wire

2 years ago

New research highlights the positive impact of GLP-1s and other anti-obesity medications on the Allurion Program

Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership

Business Wire

2 years ago

Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership

CMCT Declares Preferred Stock Dividends

Business Wire

2 years ago

CMCT Declares Preferred Stock Dividends

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

2 years ago

Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

ACCESSWIRE

2 years ago

Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

/C O R R E C T I O N -- Cadiz, Inc./

PR Newswire

2 years ago

/C O R R E C T I O N -- Cadiz, Inc./

Optimism for Eastern (NASDAQ:EML) has grown this past week, despite one-year decline in earnings

Simply Wall St.

2 years ago

Optimism for Eastern (NASDAQ:EML) has grown this past week, despite one-year decline in earnings

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

2 years ago

Brainsway Ltd. Sponsored ADR (BWAY) Is a Great Choice for 'Trend' Investors, Here's Why

Independent Bank Group (IBTX) Surges 8.7%: Is This an Indication of Further Gains?

Zacks

2 years ago

Independent Bank Group (IBTX) Surges 8.7%: Is This an Indication of Further Gains?

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

2 years ago

BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Business Wire

2 years ago

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

10 Best Debt Free Penny Stocks To Buy Now

Insider Monkey

2 years ago

10 Best Debt Free Penny Stocks To Buy Now

PureCycle Appoints Jeff Fieler as Interim CFO

ACCESSWIRE

2 years ago

PureCycle Appoints Jeff Fieler as Interim CFO

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Zacks

2 years ago

The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

Zacks

2 years ago

Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

Zacks

2 years ago

BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data

Share on Social Networks: